{"entity":{"id":"nct06057922","kind":"trial","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of YL201 for Injection in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., active and no longer recruiting.","summary":"A Study YL201 in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06057922 by MediLink Therapeutics (Suzhou) Co., Ltd., with 990 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2026-10. Interventions recorded: YL201 for Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06057922","url":"https://clinicaltrials.gov/study/NCT06057922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06057922","phase":"1/2","setting":"A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":990,"outcomes":[]},"route":"/trials/nct06057922/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}